# Results Section Consolidation Plan

## Problem Statement
Sections 07, 08, and 09 contain significant duplicate content covering detection vs forecasting comparison, clinical maturity, and readiness assessment. This plan merges these sections while preserving all unique points and shortening overall length.

---

## Current Structure Analysis

### Section 06: Performance Metrics
- Detection performance (sensitivity ranges, FPR reporting)
- Forecasting performance (sensitivity, AUC, IoC, TiW)
- **KEEP** - Covers unique metric data

### Section 07: Detection Versus Forecasting
- Clinical objectives (detection vs forecasting)
- Clinical maturity (detection ahead, ILAE benchmarks)
- Reporting practices (different metrics)
- **MERGE with 09** - Significant overlap

### Section 08: Clinical Readiness and Deployment
- Validation phase distribution
- Benchmark achievement
- Commercial device status
- Real-world deployment
- Deployment architecture
- Barriers to clinical adoption
- Most advanced approaches
- **KEEP as core** - This is the most comprehensive section

### Section 09: Detection, Forecasting, and Clinical Readiness
- Maturity comparison (duplicates 07)
- Sample size disparities
- FPR benchmark discussion (duplicates 07)
- Forecasting AUC ceiling
- **MERGE into 07 and 08** - This section is essentially a subset of 07+08

---

## Duplicate Content Mapping

| Content | Appears In | Action |
|---------|------------|--------|
| Clinical objectives (detection vs forecasting) | 07, 09 | Keep in 07, remove from 09 |
| "Detection shows greater maturity" | 07, 09 | Keep in 07, remove from 09 |
| ILAE Phase 3 benchmark citation | 07, 08, 09 | Keep in 08, remove from 07/09 |
| Commercial devices (Embrace, NightWatch) | 07, 08, 09 | Keep in 08 only |
| Spahr 0.0054/h FPR detail | 08, 09 | Keep in 08 only |
| Fine 0.023/h FPR detail | 08, 09 | Keep in 08 only |
| Forecasting AUC 0.74-0.75 | 08, 09 | Keep in 08 only |
| Sample size disparities | 09 | UNIQUE - Keep |
| Reporting practices (metrics) | 07 | UNIQUE - Keep |
| Different metrics discussion | 06, 07 | Already in 06 - remove from 07 |

---

## Proposed New Structure

### New Section 07: Detection Versus Forecasting (Condensed)
*Merge 07 + unique content from 09*

**Subsections:**
1. Clinical Objectives (from 07)
2. Maturity Comparison (from 07, removing ILAE details - those stay in 08)
3. Reporting Practices (from 07 - unique content)

**Content to keep:**
- Clinical purpose distinction
- Detection closer to translation (high-level)
- Different metrics challenge comparison
- Key finding summary

**Content to remove:**
- ILAE benchmark details (move to 08)
- Commercial device names (move to 08)
- Specific study details (Spahr, Fine - already in 08)

### New Section 08: Clinical Readiness (Expanded)
*Keep existing 08 as core, add unique content from 09*

**Subsections:**
1. Validation Phase Distribution (existing 08)
2. Benchmark Achievement (existing 08 + forecasting AUC from 09)
3. Commercial Device Status (existing 08)
4. Real-World Deployment (existing 08)
5. Deployment Architecture (existing 08)
6. Barriers to Clinical Adoption (existing 08)
7. Most Advanced Approaches (existing 08)

**Content to add from 09:**
- Sample size disparities paragraph
- Forecasting AUC ceiling paragraph (integrate into Benchmark Achievement)

### Section 09: DELETE
*All content merged into 07 and 08*

---

## Detailed Content Allocation

### From Section 07 → Keep in New 07:
- [x] Clinical objectives paragraph (detection = identify during, forecasting = predict before)
- [x] Maturity comparison (high-level: detection ahead, no forecasting benchmarks)
- [x] Reporting practices (patient-level outcomes in forecasting vs detection)
- [x] Key finding paragraph
- [x] Limitation identified paragraph

### From Section 07 → Remove (duplicates):
- [ ] ILAE systematic review citation (exists in 08)
- [ ] "0.2-0.67 per 24 hours" detail (exists in 08)
- [ ] Commercial device names (exists in 08)

### From Section 09 → Add to New 08:
- [x] Sample size disparities paragraph (median 66 vs 40)
- [x] Forecasting AUC ceiling discussion (integrate into Benchmark Achievement)

### From Section 09 → Remove (duplicates):
- [ ] Clinical objectives (identical to 07)
- [ ] "Detection shows greater maturity" (identical to 07)
- [ ] Spahr details (already in 08)
- [ ] Fine details (already in 08)
- [ ] Commercial device mentions (already in 08)
- [ ] ILAE benchmark (already in 08)

### From Section 08 → Keep Unchanged:
- [x] All subsections remain
- [x] Validation Phase Distribution
- [x] Benchmark Achievement (add forecasting AUC from 09)
- [x] Commercial Device Status
- [x] Real-World Deployment
- [x] Deployment Architecture
- [x] Barriers to Clinical Adoption
- [x] Most Advanced Approaches

---

## Estimated Length Reduction

| Section | Current Lines | Target Lines | Reduction |
|---------|---------------|--------------|-----------|
| 07 | 28 | 18 | -10 |
| 08 | 64 | 68 | +4 (adding from 09) |
| 09 | 16 | 0 | -16 |
| **Total** | **108** | **86** | **-22 lines (~20%)** |

---

## Implementation Steps

1. **Create new Section 07** (condensed from current 07)
   - Keep clinical objectives
   - Keep maturity comparison (high-level, no study details)
   - Keep reporting practices
   - Remove ILAE benchmark details
   - Remove commercial device names
   - Remove specific study results

2. **Update Section 08** (add unique content from 09)
   - Add sample size disparities paragraph
   - Integrate forecasting AUC ceiling into Benchmark Achievement
   - Keep all existing content

3. **Delete Section 09**
   - All content merged elsewhere

4. **Update cross-references**
   - Check for `\ref{sec:detection-vs-forecasting}` and `\ref{sec:detection-forecasting-readiness}`
   - Update results_main.tex to remove 09 inclusion

5. **Verify no content loss**
   - Check each unique point from 09 is captured
   - Check each unique point from 07 is preserved
   - Ensure flow is logical

---

## Content Preservation Checklist

### From Section 07 (Preserve All):
- [ ] Detection = identify during seizure for intervention
- [ ] Forecasting = predict before onset for prevention
- [ ] Detection most valuable for GTC/FBTCS seizures
- [ ] Forecasting improves quality of life by reducing uncertainty
- [ ] Detection closer to clinical translation
- [ ] Forecasting lacks clear benchmarks
- [ ] Forecasting reports patient-level success rates
- [ ] Detection rarely reports individual outcomes
- [ ] Different metrics complicate comparison
- [ ] Key finding summary
- [ ] Limitation identified

### From Section 09 (Preserve Unique Only):
- [ ] Sample size: median 66 (detection) vs 40 (forecasting)
- [ ] Largest detection: 384 patients (Spahr)
- [ ] Largest forecasting: 70 patients (Vieluf)
- [ ] Forecasting AUC consistently 0.74-0.75 (performance ceiling)

### From Section 08 (All Preserved):
- [ ] Validation phase distribution
- [ ] No Phase 3 studies achieved
- [ ] Two detection approach Phase 3
- [ ] Forecasting in earlier phases
- [ ] Commercial device status (6/13 use commercial)
- [ ] Embrace FDA 510(k), NightWatch CE
- [ ] No forecasting regulatory approval
- [ ] Home/ambulatory validation details
- [ ] Deployment architecture (on-device, cloud, offline)
- [ ] Five barriers to adoption
- [ ] Most advanced approaches (Spahr, Dong, Stirling)

---

## Key Principles for Merged Content

1. **No loss of unique information** - Every distinct point preserved
2. **No repetition** - Each point appears once
3. **Logical flow** - Objectives → Readiness → Deployment
4. **Conciseness** - Remove redundant phrases
5. **Study details consolidated** - Specific study results in one location (Section 08)

---

Created: 2026-01-27
Purpose: Consolidate Results sections 07, 08, 09 to eliminate duplication while preserving all content
